Top news this week: FDA approvals for bacterial pneumonia, cystic fibrosis
This week, the FDA grants approval on two treatments: oral omadacycline for community-acquired bacterial pneumonia and Trikafta for children aged 6 to 11 with cystic fibrosis; more than 70% of COVID-19 patients experience at least one persistent symptom; many patients self-identify the need for pulmonary rehab following COVID-19 hospitalization; and children who had mild or asymptomatic COVID-19 do not need to be cleared for sports, according to the AAP.
Read the full coverage here:
FDA approves omadacycline oral regimen for community-acquired bacterial pneumonia
FDA approves Trikafta for children aged 6 to 11 with cystic fibrosis
More than 70% of COVID-19 patients experience at least one persistent symptom
Many patients self-identify need for pulmonary rehab following COVID-19 hospitalization
AAP: Children who had mild or asymptomatic COVID-19 do not need to be cleared for sports
References:
AAP. COVID-19 interim guidance: Return to sports and physical activity. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-interim-guidance-return-to-sports/. Accessed June 10, 2021.
Daynes E, et al. New Insights in Pulmonary Rehabilitation. Presented at: American Thoracic Society International Conference; May 14-19, 2021 (virtual meeting).
Nasserie T, et al. JAMA Netw Open. 2021;doi:10.1001/jamanetworkopen.2021.11417.
Collapse
Read more about
